🚀 Showcase Alert! September 12 at 11:30AM, Tezcat Biosciences will be presenting at LSX World Congress on the Biotech Stage! 🚀
Craig Ramirez, Ph.D. will be discussing Tezcat’s cutting-edge receptor-independent drug delivery technology, specifically targeting mutant RAS solid tumors and myeloma. Tezcat’s lead asset, TZT-102, is a revolutionary protein-drug conjugate with a novel mechanism of action. Unlike traditional therapies, TZT-102 tackles mutant RAS cancers by addressing the metabolic and phenotypic effects of mutant RAS signaling, offering a broader impact across all RAS cancers. It's designed to be resistant to drug resistance and boasts a superior therapeutic index compared to FDA-approved antibody-drug conjugates.
This breakthrough offers new hope for adult patients facing these challenging conditions.
Don’t miss this opportunity to learn about Tezcat's game-changing innovations in oncology!
#LSXWorldCongress#PrecisionMedicine#Oncology#Biotech#DrugDevelopment#LSXUSA
Tezcat Biosciences Co-Founder & CEO ; Illumaras Co-Founder
We recently won Top Presenter for the Life Sciences/Healthcare Track at the New York Venture Summit. If you missed this event, I will be presenting the story behind Tezcat Biosciences at the LSX World Congress USA on September 12th in Boston. I look forward to seeing you there. LSX USA Congress
What an Inspiring Experience at the Vesalius Innovation Award!
I had the incredible opportunity to attend the Vesalius Innovation Award at the STM Innovation Fair, and I’m still buzzing with excitement!
A huge congratulations to the Winner: Knowledge Gate Group 🏆—your innovation truly stood out, and it’s clear that you’re making waves in the STM space. Your work is nothing short of groundbreaking, and I can’t wait to see how you continue to shape the future of scientific knowledge and innovation.
Shoutout to the Runner-ups 💡 Prof. Valmed® - validated medical information GmbH and 💡 Clear Skies! Your projects were nothing less than extraordinary. Your dedication, creativity, and impact were felt by everyone in the room. Reaching this stage is a massive achievement, and it’s just the beginning of something even greater.
To all the participants—thank you for your passion, your vision, and your courage to innovate. The energy and creativity you brought to the event left me incredibly inspired. It’s clear that the future of STM innovation is in excellent hands.
Events like these remind me of the power of community, collaboration, and innovation. I’m excited to see how these projects grow and how each of you continues to push boundaries and drive progress in the industry.
A huge thanks to the organizers and everyone behind the scenes for creating a platform where bold ideas can thrive and for bringing such an inspiring community together.
Here’s to more collaboration, more breakthroughs, and a future driven by innovation! 🚀
#Innovation#VesaliusInnovationAward#STMFair#KnowledgeGateGroup#ProfValmed#ClearSkies#FutureOfKnowledge#Inspiration#Collaboration#PushingBoundaries#STMPublishing#ScientificInnovation#TechForGood
Looking forward to conversations around therapies and technology progressing with improved investor sentiment, albeit with caution!
Investing?
How commercially viable is the science? What are the product development/CMC and regulatory/clinical risks? What is the competitive landscape?
Fundraising?
Does your pitch deck and data room position your company to be as investable as possible?
Promising non-clinical data?
How to turn that into a commercial product? What is the best product development and regulatory strategy?
Growing pains?
Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another!
Let’s connect and discuss how Boyds can help!
#REAIBoston2024#BiotechweekBoston
Tomorrow, Senior Director of Business Development, Ami Patel will be at RESI Boston 2024 📍
The Redefining Early Stage Investments (RESI) conference series connects start-ups and early-stage investors and strategic channel partners.
If you would like to schedule a meeting with Ami to discuss how Boyds can support your drug development program, contact info@boydconsultants.com.
#RESIBoston2024#RESI2024#LifeScienceLife Science Nation
Bio€quity Europe is off to an outstanding start with the convergence of life sciences companies, investors, local and EU government, and those of us who support our clients in further support of advancing global public health!
Our session today was moderated by Selina Koch, PhD , BioCentury Inc. and included Jennifer McMahon, Seroba, Edward Kliphuis, Sofinnova Partners,
John W Cassidy, Kindred Capital VC, Florent Gros, Earlybird Venture Capital. I was thrilled to join such an outstanding group of investors to discuss the opportunities for AI to influence drug discovery, research and development!
#BioEquityEurope
Next week I’ll be joining the Ori team at #CGMesa24 in Arizona.
Two things you should not miss:
1️⃣ Panel Discussion on Mon, 7th at 7:45 AM: Gain insights into pre-clinical development strategies to help safeguard commercial success. 💡
2️⃣ IRO Platform Demo: See our cutting-edge IRO technology in action. Be sure to book your demo slot before they fill up! 🤖
Please come say hello and let's chat about driving innovation forward, together!
#manufacturingbrighterfutures
📍You are invited to join the Ori team in Boston to experience IRO® - the New Standard of CGT Manufacturing
On September 17th join us, Jason C. Foster, Ori Biotech CEO and Matthew Hewitt, Vice President, CTO Manufacturing at Charles River Laboratories for an evening with IRO, where we'll be showcasing:
🔹 New real-world data from the platform
🔹 In-person IRO demos
If you'd like to see an IRO in-person (trust us, you do!) and dive into the data – showing how it automates better biology, accelerates product development and helps to scale your impact, secure your place today ➡️ https://lnkd.in/ep6p_DZ3#IRO#TheNewStandard#AutomateBetterBiology#AccelerateProductDevelopment#ScaleYourImpact
Really enjoyed my time at the ELRIG UK Research & Innovation meeting in Manchester! Great to hear many interesting talks from people across the industry, and present some of our recent work at Newcells Biotech ☺️
We connect consultants & investors with top healthcare experts for consultations, deal advisory, placement or board memberships. I also send 1 email 💌/week to elevate your expertise (1.5K+ Subs) 👉 bit.ly/Alexis-BTHT
🧬🇪🇺 Top VC Investors in European Life Sciences From 2017 to 2021
European life sciences have seen vibrant VC activity over the years, with top regional and global investors shaping the landscape. Here's an overview based on insights from FCF Life Sciences:
🔹 Top European Seed Investors
HTGF | High-Tech Gründerfonds leads with 23 seed transactions, focusing mainly on German companies.
🔹 Series A Leaders 🐓
Dominated by Bpifrance and Sofinnova Partners, French investors with regional influence.
🔹 Later-Stage Investments
Novo Holdings (Denmark) takes the lead, backing mature-stage European life sciences ventures.
🔹 US Investor Contributions
While European investors dominate, US-based SOSV stands out as the only investor with 20+ seed transactions in Europe (2017–2021). Other notable US players include Epidarex Capital, OrbiMed, and RA Capital Management.
Source :FCF Life Sciences
#Investors#VentureCapital#LifeSciences
———
I am Alexis, a French pharmacist turned entrepreneur. My company BTHT connects consultants and investors with healthcare experts for calls, advisory and board memberships.
For more content like this 👇
Join 16K+ followers by clicking my name + follow 🔔
Join 1.5K+ subscribers to my weekly newsletter 💌